| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Divisions of Experimental Oncology D [S. S., F. S., F. A., A. A., G. P., M. S.] and Pathology [S. R., C. C.], Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, and S. Gerardo Hospital, via Donizetti 105, 20052 Monza [M. S., G. B., E. C.], Italy
We have shown previously that peripheral blood lymphocytes (PBL) of patients with metastatic melanoma include cytotoxic T-cell clones that recognize Melan-A/MART-1 in a HLA-A2-restricted fashion. Such clones preferentially use the variable (V) regions TCRBV14 or TCRBV7 in the ß-chain of their T-cell receptor (TCRB). It was not known, however, whether this finding is associated with the presence of the HLA-A2 allele in tumor tissue and whether evidence of the predominance of these TCRBV families can also be observed in primary tumor tissue. To address these issues, we have used a semiquantitative PCR to examine the TCRBV repertoire in six HLA-A2-matched primary melanomas in comparison with their autologous PBL. Although each patient had his or her own pattern of skewed TCRBV utilization, in all patients, T-cells that used TCRBV14 were significantly overrepresented in the neoplastic site compared with PBL. All of the primary tumors studied had detectable expression of Melan-A/MART-1 and gp100, and immunohistochemical analysis confirmed the presence of the HLA-A2 allele. Additional samples of Melan-A/MART-1-positive, gp100-positive primary melanomas from six non-HLA-A2 patients and four autologous normal skin controls failed to reveal a TCRBV14 predominance in such tissues. These results point to a role of TCRBV14 T lymphocytes in the HLA-A2-restricted immune recognition of primary melanomas.
1 This work was supported by the Italian Association for Cancer Research (Milan, Italy).
2 To whom requests for reprints should be addressed.
Received 2/13/95. Accepted 5/31/95.
This article has been cited by other articles:
|
|
 |
|
  J. Manne, M. J. Mastrangelo, T. Sato, and D. Berd TCR Rearrangement in Lymphocytes Infiltrating Melanoma Metastases After Administration of Autologous Dinitrophenyl-Modified Vaccine J. Immunol., September 15, 2002; 169(6): 3407 - 3412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Clay, A. C. Hobeika, P. J. Mosca, H. K. Lyerly, and M. A. Morse Assays for Monitoring Cellular Immune Responses to Active Immunotherapy of Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1127 - 1135. [Abstract] [Full Text]
|
|
|
|
|
|
F. Wang, E. Bade, C. Kuniyoshi, L. Spears, G. Jeffery, V. Marty, S. Groshen, and J. Weber Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma Clin. Cancer Res., October 1, 1999; 5(10): 2756 - 2765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Rezvany, M. Jeddi-Tehrani, A. Osterborg, E. Kimby, H. Wigzell, and H. Mellstedt Oligoclonal TCRBV Gene Usage in B-Cell Chronic Lymphocytic Leukemia: Major Perturbations Are Preferentially Seen Within the CD4 T-Cell Subset Blood, August 1, 1999; 94(3): 1063 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. thor Straten, P. Guldberg, K. Gronbak, M. R. Hansen, A. F. Kirkin, T. Seremet, J. Zeuthen, and J. C. Becker In Situ T Cell Responses Against Melanoma Comprise High Numbers of Locally Expanded T Cell Clonotypes J. Immunol., July 1, 1999; 163(1): 443 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. thor Straten, P. Guldberg, T. Seremet, R. A. Reisfeld, J. Zeuthen, and J. C. Becker Activation of preexisting T cell clones by targeted interleukin 2 therapy PNAS, July 21, 1998; 95(15): 8785 - 8790. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
